O'Brien et al 2025 — Green-light analgesia via endocannabinoid system in OA rats
One-paragraph summary
Mechanism paper resolving how green-light therapy (GLT) produces analgesia at the molecular level. Wistar rats (male and female, 207-318 g) received intra-articular sodium monoiodoacetate (3 mg in 50 μL saline) to induce knee OA. On day 9, animals were exposed to either neutral-white 4000K light (20 lux) or green light (525 nm, 20 lux) for 5 days, 8 hours per day. Joint nociception measured by von Frey hair algesiometry (mechanical), dynamic weight bearing, and in vivo single-unit extracellular recordings from knee joint mechanonociceptors. Result: GLT significantly reduced secondary mechanical hypersensitivity in both sexes and improved hindlimb weight bearing in females only. No effect on joint nociceptor activity in either sex — meaning the analgesia is central rather than peripheral-nociceptor-level. Serum lipidomics indicated increased circulating analgesic endolipids in response to GLT, particularly the N-acyl-glycines. Partial blockade of the endocannabinoid system with the GPR-18 / CB-1 antagonist AM281 (500 μg/kg i.p.) attenuated GLT-induced analgesia, demonstrating that the endocannabinoid system is required for the green-light analgesic effect. For the project, this is the mechanism anchor for the v0.3.1 §12.7 green-light arm — green light upregulates circulating N-acyl-glycine analgesic endolipids that engage the endocannabinoid system, producing central pain modulation that is wavelength-specific. Companion paper to O'Brien et al 2026 Can J Pain (human knee OA crossover trial, ingested simultaneously); together they provide the human + rat + mechanism trilogy.
Claims as triples
green_light_exposure — modulates → widespread_pain[evidence: secondary mechanical hypersensitivity reduction both sexes in OA rat model; confidence: emerging]green_light_exposure — modulates → endocannabinoid_system[evidence: AM281 GPR-18/CB-1 antagonism attenuates GLT analgesia; confidence: emerging]green_light_exposure — causes → analgesic_endolipid[evidence: serum lipidomic increase in N-acyl-glycines post-GLT; confidence: emerging]green_light_exposure — modulates → central_sensitization[evidence: secondary hypersensitivity reduction without peripheral nociceptor effect implicates central modulation; confidence: emerging]
Methods note
Animal model: Wistar rats, male + female. OA induction: intra-articular sodium monoiodoacetate (3 mg in 50 μL saline). Intervention day 9: 5-day exposure × 8 hours/day to either neutral-white 4000K light (20 lux) or green light (525 nm, 20 lux). Pain assessments: von Frey hair algesiometry for mechanical sensitivity; dynamic weight bearing for limb-use asymmetry; in vivo single-unit extracellular recordings from knee joint mechanonociceptors. Lipidomic analysis: serum-extracted lipid panel via LC-MS or equivalent. Pharmacological dissection: AM281 (GPR-18/CB-1 antagonist) 500 μg/kg i.p. to block endocannabinoid system. Statistical analysis: sex-stratified comparison.
Limitations
- OA rat model — translation to FM is by mechanism analogy. The endocannabinoid mechanism likely operates similarly in FM but is not directly tested.
- Sex-specific weight-bearing finding (improvement only in females) is mechanistically unresolved. Both sexes show reduced mechanical hypersensitivity but only females show weight-bearing change. May reflect hormone modulation of the endocannabinoid pathway.
- AM281 partial blockade — endocannabinoid attenuation but not complete abolition. Other mechanisms (descending inhibition, opioid system) may co-contribute.
- Single-laboratory finding; the McDougall lab has produced multiple green-light papers including the companion O'Brien 2026 human trial. Independent replication of the endocannabinoid mechanism would strengthen the claim.
Open questions raised
- Are N-acyl-glycines elevated in plasma of human FM patients receiving green-light therapy? Direct biomarker test of the loop.
- Does green-light analgesia work in FM patients with CB-1 polymorphisms that affect endocannabinoid signaling? Could identify responder vs. non-responder predictors.
- Does combining green light with a peripherally-acting cannabinoid agent (FAAH inhibitor, CBD) produce synergistic analgesia? Combination-therapy designs become plausible.
Triangulation notes
- Closes the mechanism gap for v0.3.1 §12.7 green-light arm. The arm now has mechanism (this paper), human evidence (O'Brien 2026 Can J Pain), animal-model predictive validity (Ferrari 2026 PAIN in Dahl SS rats), and consolidating mini-review (Dai et al 2025 Front Pain Res).
- Bridges to the cannabinoid-FM literature. Cannabis and CBD have established but mixed evidence in FM; the endocannabinoid mechanism resolved here suggests green-light + cannabinoid combinations could be synergistic. This is a potential bridge B21+ candidate.
- Compatible with the network-FC framework — secondary hypersensitivity reduction without peripheral effect implicates central modulation, consistent with descending-inhibition or thalamocortical-gating effects (the Tan et al 2025 V2M-LP circuit paper, ingested simultaneously, provides one candidate circuit).
- PAIN peer-reviewed — promotes the mechanism to peer-review tier.
Bridges
- B21 candidate strengthened — green-light therapy ↔ FM via endocannabinoid-mediated central pain modulation.
- New candidate B22 — endocannabinoid-system-modulating interventions (green light, CB-1 agonists, CBD, FAAH inhibitors) as a unified class. Drug-class-defined bridge for chronic-pain conditions.